Barclays
ASMB icon

Barclays’s Assembly Biosciences ASMB Stock Holding History

Barclays’s Portfolio ASMB Stock Details ASMB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$751K Buy
27,050
+2,309
+9% +$65.9K ﹤0.01% 2932
2025
Q4 		$841K Buy
24,741
+20,780
+525% +$669K ﹤0.01% 3558
2025
Q3 		$101K Buy
3,961
+1,182
+43% +$25.9K ﹤0.01% 4610
2025
Q2 		$50.4K Sell
2,779
-652
-19% -$8.6K ﹤0.01% 4708
2025
Q1 		$32.8K Buy
3,431
+437
+15% +$5.71K ﹤0.01% 4702
2024
Q4 		$47.2K Sell
2,994
-41
-1% -$660 ﹤0.01% 4775
2024
Q3 		$46K Buy
3,035
+41
+1% +$624 ﹤0.01% 4765
2024
Q2 		$41.1K Hold
2,994
– – ﹤0.01% 4288
2024
Q1 		$39.8K Hold
2,994
– – ﹤0.01% 4662
2023
Q4 		$29.5K Hold
2,994
– – ﹤0.01% 4850
2023
Q3 		$31.8K Hold
2,994
– – ﹤0.01% 4039
2023
Q2 		$41.3K Hold
2,994
– – ﹤0.01% 3915
2023
Q1 		$30.2K Hold
2,994
– – ﹤0.01% 4570
2022
Q4 		$46.7K Sell
2,994
-106
-3% -$1.81K ﹤0.01% 4577
2022
Q3 		$61K Sell
3,100
-10,302
-77% -$249K ﹤0.01% 3718
2022
Q2 		$337K Sell
13,402
-94
-0.7% -$2.16K ﹤0.01% 3116
2022
Q1 		$333K Hold
13,496
– – ﹤0.01% 3143
2021
Q4 		$378K Sell
13,496
-4,252
-24% -$139K ﹤0.01% 3320
2021
Q3 		$742K Buy
17,748
+4,235
+31% +$178K ﹤0.01% 2964
2021
Q2 		$628K Buy
13,513
+772
+6% +$38.2K ﹤0.01% 2940
2021
Q1 		$703K Buy
12,741
+1,265
+11% +$83.8K ﹤0.01% 2988
2020
Q4 		$833K Buy
11,476
+5,779
+101% +$678K ﹤0.01% 2888
2020
Q3 		$1.13M Sell
5,697
-7,413
-57% -$1.87M ﹤0.01% 2590
2020
Q2 		$3.67M Buy
13,110
+38
+0.3% +$8.87K ﹤0.01% 1611
2020
Q1 		$2.33M Buy
13,072
+867
+7% +$186K ﹤0.01% 2156
2019
Q4 		$3M Buy
12,205
+6,007
+97% +$1.11M ﹤0.01% 2568
2019
Q3 		$732K Sell
6,198
-2,293
-27% -$347K ﹤0.01% 3932
2019
Q2 		$1.38M Buy
8,491
+7,837
+1,198% +$1.49M ﹤0.01% 3347
2019
Q1 		$155K Buy
654
+23
+4% +$5.82K ﹤0.01% 5017
2018
Q4 		$171K Sell
631
-201
-24% -$58.1K ﹤0.01% 4678
2018
Q3 		$371K Buy
832
+483
+138% +$226K ﹤0.01% 4508
2018
Q2 		$165K Sell
349
-333
-49% -$176K ﹤0.01% 4875
2018
Q1 		$402K Buy
682
+469
+220% +$291K ﹤0.01% 4182
2017
Q4 		$116K Buy
213
+149
+233% +$67.4K ﹤0.01% 5130
2017
Q3 		$27K Buy
64
+63
+6,300% +$19.3K ﹤0.01% 5660
2017
Q2 		$0 Sell
1
-2,080
-100% -$586K ﹤0.01% 6621
2017
Q1 		$637K Buy
+2,081
New +$511K ﹤0.01% 3166
2016
Q3 		– Sell
-298
Closed -$20K – 6589
2016
Q2 		$20K Buy
+298
New +$19.6K ﹤0.01% 5266
2015
Q4 		– Sell
-6
Closed -$1K – 5973
2015
Q3 		$1K Sell
6
-17
-74% -$2.99K ﹤0.01% 6488
2015
Q2 		$5K Buy
+23
New +$4.44K ﹤0.01% 6424
2014
Q3 		– Sell
-2
Closed – – 7640
2014
Q2 		$0 Hold
2
– – ﹤0.01% 7589
2014
Q1 		$0 Buy
+2
New +$312 ﹤0.01% 7561
2013
Q4 		– Sell
-94
Closed -$17.1K – 7516
2013
Q3 		$11K Sell
94
-470
-83% -$72K ﹤0.01% 6744
2013
Q2 		$81K Buy
+564
New +$88.4K ﹤0.01% 5964

Other funds holding ASMB

GS
Gilead Sciences Foster City, California $2.12B AUM 143.53% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
PHP
Parkman Healthcare Partners Stamford, Connecticut $970M AUM 79.46% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return

Barclays's ASMB Position: Q1 2026 in Review

Barclays increased its Assembly Biosciences (ASMB) stake by 9.3% in Q1 2026, buying an estimated $65.9K and bringing the position to 27,050 shares worth $751K. The position accounts for ﹤0.01% of the portfolio, ranked #2932.

Barclays first reported a position in ASMB in Q2 2013 and has held it in 44 quarters since. The position peaked at $3.67M in Q2 2020. 75 funds tracked by Wall St. Rank hold ASMB as of Q1 2026.

  • Barclays held 27,050 shares of Assembly Biosciences worth $751K as of Q1 2026.
  • Barclays bought 2,309 Assembly Biosciences shares in Q1 2026, an estimated $65.9K.
  • Assembly Biosciences made up ﹤0.01% of Barclays's portfolio in Q1 2026, its #2932 holding.
  • Barclays first reported a position in Assembly Biosciences in Q2 2013 and has held it in 44 quarters since.
  • Barclays's Assembly Biosciences position peaked at $3.67M in Q2 2020.
  • 75 funds tracked by Wall St. Rank held Assembly Biosciences as of Q1 2026.

Based on Barclays's 13F filing for Q1 2026, filed 15 May 2026.